Evidence map›Paper›PMID 37310797›Full record

ArticleThe oncologist2023

Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG).

Carolien P Schröder, Elise van Leeuwen-Stok, Fatima Cardoso, Barbro Linderholm, Coralie Poncet, Antonio C Wolff, Vesna Bjelic-Radisic, Gustavo Werutsky, Miguel H Abreu, Ivana Bozovic-Spasojevic and 13 more

Open access · goldAbstract read
In one paragraph

Article in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 20 institutions in 7 countries.

Carolien P SchröderDepartment Medical Oncology, Netherlands Cancer Institute Amsterdam and University Medical Center Groningen, The Netherlands.
Elise van Leeuwen-StokDutch Breast Cancer Trialists' Research Group (BOOG), The Netherlands.
Fatima CardosoBreast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
Barbro LinderholmDepartment of Oncologym, Sahlgrenska University Hospital, Gothenburg, Sweden and Swedish Association of Breast Oncologists (SABO), Sweden.
Coralie PoncetEuropean Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
Antonio C WolffDepartment of Medical Oncology, Johns Hopkins, Baltimore, MD, USA.
Vesna Bjelic-RadisicBreast Unit, Helios University Clinic, Wuppertal, University Witten/Herdecke, Germany.
Gustavo WerutskyLatin American Cooperative Oncology Group, Porto Alegre, Brazil.
Miguel H AbreuDepartment of Medical Oncology, Portuguese Institute of Oncology of Porto, Porto, Portugal.
Ivana Bozovic-SpasojevicDepartment of Medical Oncology, Institute of Oncology and Radiology, Belgrade, Serbia.
Irma den HoedDepartment of Medical Oncology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, The Netherlands.
Aafke H HonkoopDepartment of Medical Oncology, Isala, Zwolle, The Netherlands.
Maartje LosDepartment of Medical Oncology, St. Antonius Ziekenhuis, Utrecht, The Netherlands.
Jose P LeoneDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Nicola S RussellDepartment of Radiotherapy, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Tineke J SmildeDepartment of Medical Oncology, Jeroen Bosch Ziekenhuis's Hertogenbosch, The Netherlands.
Annette W G van der VeldenDepartment of Medical Oncology, Martini Ziekenhuis, Groningen, The Netherlands.
Catherine Van PoznakDepartment of Medical Oncology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-5523-6908
Marije M VleugelDepartment of Medical Oncology, Waterlandziekenhuis, Purmerend, The Netherlands.
Rachel L YungDepartment of Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Corneel CoensEuropean Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
Sharon H GiordanoDepartment of Health Services Research and Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Kathryn J RuddyDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-6298-332X
European Organisation for Research and Treatment of Cancer · BEChampalimaud Foundation · PTElisabeth-TweeSteden Ziekenhuis · NLHarvard University · USHelios Universitätsklinikum Wuppertal · DEInstituto Português de Oncologia Francisco Gentil · PTIsala · NLJeroen Bosch Ziekenhuis · NLJohns Hopkins University · USMartini Ziekenhuis · NLMayo Clinic in Arizona · USOncology Institute of Vojvodina · RSSahlgrenska University Hospital · SESt. Antonius Ziekenhuis · NLThe Netherlands Cancer Institute · NLThe University of Texas MD Anderson Cancer Center · USUniversity Medical Center Groningen · NLUniversity of Michigan · USUniversity of Washington · USWaterlandziekenhuis · NL

Funding

Institutional Career Development CoreKL2TR002379 · NCATS · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2017 to 2026
$14.9M
NCATS NIH HHS KL2 TR002379
6 · The paper itself

Abstract

introductionProspective data about quality of life (QoL) in men with breast cancer (BC) are lacking. A prospective registry (EORTC10085) of men with all BC stages, including a QoL correlative study, was performed as part of the International Male Breast Cancer Program.

methodsQuestionnaires at BC diagnosis included the EORTC QLQ-C30 and BR23 (BC specific module), adapted for men. High functioning and global health/QoL scores indicate high functioning levels/high QoL; high symptom-focused measures scores indicate high symptoms/problems levels. EORTC reference data for healthy men and women with BC were used for comparisons.

resultsOf 422 men consenting to participate, 363 were evaluable. Median age was 67 years, and median time between diagnosis and survey was 1.1 months. A total of 114 men (45%) had node-positive early disease, and 28 (8%) had advanced disease. Baseline mean global health status score was 73 (SD: 21), better than in female BC reference data (62, SD: 25). Common symptoms in male BC were fatigue (22, SD: 24), insomnia (21, SD: 28), and pain (16, SD: 23), for which women's mean scores indicated more burdensome symptoms at 33 (SD: 26), 30 (SD: 32), and 29 (SD: 29). Men's mean sexual activity score was 31 (SD: 26), with less sexual activity in older patients or advanced disease.

conclusionsQoL and symptom burden in male BC patients appears no worse (and possibly better) than that in female patients. Future analyses on impact of treatment on symptoms and QoL over time, may support tailoring of male BC management.

Indexed as

Breast NeoplasmsBreast Neoplasms, MaleAgedChild, PreschoolFemaleHealth StatusHumansMaleProspective StudiesQuality of LifeSurveys and Questionnairesmale breast cancerprospective studyquality of lifesymptom assessment

Identifiers

PMID37310797
PMCPMC10546813
OpenAlexW4380538123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.